AL Amyloidosis: Testing for Hidden Disease After Transplant
Part of Cancer, Hormones & metabolism, Immune system & allergy clinical trials.
This study looks for 'minimal residual disease' (tiny traces of amyloid after treatment) in people with AL amyloidosis who have had a stem cell transplant. It helps doctors understand if more treatment is needed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have been newly diagnosed with AL amyloidosis (amyloid made from light chain proteins).
- You are eligible for and willing to have a stem cell transplant (ASCT).
- You have achieved a complete hematologic response (no detectable abnormal light chains) after 2–4 cycles of Dara-CyBorD chemotherapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called NXC-201 against a common combination therapy (daratumumab with CyBorD) for people newly diagnosed with AL amyloidosis who have not received treatment before. The goal is to see if NXC-201 works better at controlling the disease and is safe.
This trial is for people with AL amyloidosis who are being treated with daratumumab, bortezomib, and dexamethasone. It looks at how quickly a certain blood protein (called dFLC) drops after treatment starts and whether that predicts a complete remission.
This trial tests a combination of two targeted drugs for people newly diagnosed with AL amyloidosis. You may qualify if you have a specific genetic marker (t(11;14)) and your organs are working well enough.
This trial tests a new bispecific antibody treatment for people newly diagnosed with AL amyloidosis. The drug targets BCMA on myeloma cells and CD3 on immune cells to help your body fight the disease.
This early-stage trial tests a new cell therapy using your own immune cells (genetically modified to target amyloid-producing cells) to treat light chain amyloidosis that hasn't responded to standard treatments. The goal is to help patients whose disease has come back or stopped responding to previous therapies.
This trial tests a new drug combination for people with a specific type of AL amyloidosis (light chain amyloidosis) that has a genetic marker called t(11;14). The treatment includes Sonrotoclax (a targeted therapy) plus steroids, and possibly another drug called daratumumab, to see if it can help control the disease.
Hear when a new Light Chain (AL) Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.